ZYMEWORKS INC (ZYME)
Health Care · biotechnology · NASDAQ
A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets.
What ZYMEWORKS INC does
Zymeworks is a global biotechnology company that develops multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases. The company employs an asset and royalty aggregation strategy, focusing on advancing its own therapeutic pipeline while managing royalties from licensed assets like zanidatamab.
Themes: oncology, autoimmune disease treatment, biopharmaceutical royalty portfolio, bispecific antibody technology
Fundamentals
- Price$28.67 as of 2026-08-21 close
- Market cap$2.0B as of 2026-08-21
- 1-year return+99.2% 2025-08-21 close $14.39 → 2026-08-21 close $28.67
- P/En/a negative earnings
- Net margin-126.3% as of 2026-08-24
- ROE-37.8% as of 2026-08-24
- Debt / equity1.51 as of 2026-08-24
- Revenue growth (YoY)+3.3% as of 2026-08-24
- Revenue CAGR (3y)-36.4% SEC XBRL
- Beta1.15 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ZYME compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ZYME is not currently in any published Top 10 list. Its scores are below.
Long-term score
26.9 #1582 of 1,605 scored · #191 of 195 in Health Care
Long-term trend 74th (over the past 12 months this stock beat the market by 78.8 percentage points) and valuation 24th (price to book 7.4); weakest is profitability (4th, operating margin -140.3%, return on equity -37.8%).
Short-term score
48.3 #772 of 1,698 scored · #140 of 236 in Health Care
Volume and participation 88th: trading volume is about normal versus its 30-day average; trend 75th: the price is 12% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 17th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How ZYMEWORKS INC looks technically
ZYMEWORKS INC (ZYME) is trading 18.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 3.6% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 18.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.32 | $24.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.29 | $24.29 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal | 1 session |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 18.0% above | +18.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 28.9 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70) | 71.4 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($21.97 to $28.74) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $29.75 | $29.75 |
|---|---|---|
| From the 52-week high | it is 3.6% below its 52-week high (its highest price of the past year) | -3.6% |
| Above the 52-week low | it is 119.6% above its 52-week low (its lowest price of the past year) | +119.6% |
| Below the 52-week high | it is 3.6% below its highest point of the past year | 3.6% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $59.03 (set on 2021-01-12) | $59.03 |
| Given back of the 52-week move | over the past year its closes ranged ($13.94 to $28.67), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.10 to $19.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 51.4% below its all-time high | -51.4% |
| Nearest price level | it is trading 2.4% above a support level at $27.97 — a price it turned at twice since 2025-12-22, most recently on 2026-03-10. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.4% |
| All-time low | its lowest closing price on record is $4.11 (set on 2022-09-07) | $4.11 |
| Above the all-time low | it is 597.6% above its all-time low | +597.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.13 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.13 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $20.54 and $27.97 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $20.54 – $24.26 – $27.97 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (18.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.80× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.3% since the prior reading | +1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.01 toward buy |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.5% |
|---|---|---|
| Open gap | it gapped 4.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 26.07 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.0% |
| Gap filled | a 2.0% gap up opened on 2026-08-11 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 7 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.9 percentage points (the stock gained 19.2% while the market gained 2.3%) | +16.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.1 percentage points (the stock gained 14.2% while the market gained 3.1%) | +11.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 15.1 percentage points (the stock gained 26.2% while the market gained 11.1%) | +15.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 78.8 percentage points (the stock gained 99.2% while the market gained 20.5%) | +78.8% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.2% of the share price. | +11.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $24.56 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +16.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $25.54 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +12.3% |
Price levels it has turned at before
ZYME last closed at $28.67 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $27.97 | Support | 2.4% below the last close | turned there twice · 2025-12-22 to 2026-03-10 |
| $27.29 | Support | 4.8% below the last close | turned there four times · 2025-12-08 to 2026-07-09 |
| $26.19 | Support | 8.7% below the last close | turned there twice · 2025-11-17 to 2026-05-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.15 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$40.33 range $31.00 – $58.00; median $38.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ZYME
- Consensus EPS estimate$1.61 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant operating losses and an accumulated deficit.","Dependency on the clinical success and regulatory approval of product candidates.","Uncertainty regarding the timing and realization of future royalty and milestone cash flows."]
What changed in the latest 10-Q
AI-assisted comparison of ZYME's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'interim condensed consolidated financial statements' in newer filing (2026-05-07) vs. 'financial statements' in older filing (2025-11-06)
- Reference to Form 10-K filed March 2, 2026 for year ended December 31, 2025 in newer filing vs. Form 10-K filed March 5, 2025 for year ended December 31, 2024 in older filing
- Addition of 'global biotechnology company managing a portfolio of licensed healthcare assets' descriptor in newer filing
- Addition of 'asset and royalty aggregation strategy' language in newer filing's Overview section
- Reference to 'pasritamig' as a licensed product candidate in newer filing
- Reference to 'strategic plan announced in 2025' emphasizing 'disciplined capital allocation' in newer filing
- Addition of multi-year planning framework and structured spending framework language in newer filing
- Addition of 'Our Strategy' section with detailed strategy elements in newer filing
- Addition of specific acquisition evaluation factors (Strategic fit, Royalty potential, etc.) in newer filing
- Reference to zanidatamab royalties and regulatory milestone payments as actual revenue sources in newer filing
- Removed:
- Description of company as 'clinical-stage biotechnology company' removed in newer filing
- Removal of detailed description of zanidatamab's mechanism and HER2-targeting details from Overview section in newer filing
- Removal of specific regulatory milestones (FDA accelerated approval 2024, NMPA approval May 2025, EC approval July 2025) from Overview in newer filing
- Removal of reference to HERIZON-GEA-01 study PFS data expected in 4Q-2025 in newer filing
- Removal of 'Wholly-Owned Pipeline' section heading and detailed description in newer filing (text appears truncated)
- Reworded:
- Changed from 'difficult-to-treat diseases such as cancer and autoimmune and inflammatory diseases ("AIID")' to 'difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease' in newer filing
- Changed from 'clinical-stage' to 'global' in company descriptor
- Changed from detailed zanidatamab development narrative to brief reference focused on royalty aspects
- Changed from 'our strategic partners' to 'our strategic partners'' in revenue discussion (possessive form adjustment)
- Changed from 'we do not expect to do so until such time as we obtain regulatory approval' to 'we do not expect to do so until such time as we or our strategic partners' obtain regulatory approval' in newer filing
- Changed funding sources language from 'follow-on public offerings, including the issuance of pre-funded warrants' to 'follow-on public offerings, and private placements including the issuance of pre-funded warrants' in newer filing
- Changed net loss reference from 'nine months ended September 30, 2025' to 'three months ended March 31, 2026' reflecting different reporting periods
- Changed accumulated deficit from '$886.5 million' to '$1,073.8 million' reflecting updated financial position
- Changed financing total from '$1,019.4 million' to '$1,035.6 million' from inception
- Changed cash resources from '$299.4 million' to '$403.8 million' as of respective dates
- Notes:
- Both filings contain forward-looking statement disclaimers with identical substantive language
- Older filing text appears truncated at 'expected clinical differenti[ation]', preventing complete comparison of final sections
- Financial figures differ due to different reporting periods (Q3 2025 vs. Q1 2026) rather than restatements
- Strategic emphasis shift from product development details to royalty/licensing portfolio management is evident but reflects business model evolution
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2026-01-12. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZYME's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ZYME as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 7,483,336
- Reported value $187,382,727
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ZYME had 4,106,590 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ZYME had 5.79% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.9 days to cover at the same settlement.
- Reported short interest (shares) 4,106,590
- Short interest (% of shares outstanding) 5.79%
- Prior settlement (shares) 4,102,257
- Reported change 0.11%
- Days to cover (reported) 10.9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (SGEN)
- Genmab (GMAB)
- MacroGenics (MGNX)
- Theravance Biopharma (TBPH)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZYME vs…
ZYMEWORKS INC is found in…
Frequently asked questions
What does ZYMEWORKS INC (ZYME) do?
Zymeworks is a global biotechnology company that develops multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases. The company employs an asset and royalty aggregation strategy, focusing on advancing its own therapeutic pipeline while managing royalties from licensed assets like zanidatamab.
What sector is ZYMEWORKS INC (ZYME) in?
ZYMEWORKS INC (ZYME) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ZYMEWORKS INC's (ZYME) competitors?
Notable peers of ZYMEWORKS INC (ZYME) include Seagen, Genmab, MacroGenics and Theravance Biopharma. This peer set is informational only — not financial advice.
Is ZYMEWORKS INC (ZYME) overbought or oversold right now?
ZYMEWORKS INC (ZYME) is currently in overbought territory (its 14-day RSI is 71, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZYME come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.